J.P. Morgan analyst Tessa Romero has maintained their bullish stance on CYTK stock, giving a Buy rating on November 10.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tessa Romero’s rating is based on the promising prospects of Cytokinetics’ drug, aficamten, particularly in the treatment of obstructive hypertrophic cardiomyopathy (oHCM). The drug has shown positive clinical data, and there is an anticipation of its approval in the U.S. by the end of 2025, followed by a potential European launch in the first half of 2026. These developments are expected to support a strong market entry and adoption.
Furthermore, Cytokinetics is preparing for a differentiated label and risk evaluation and mitigation strategy (REMS) for aficamten, which could enhance its competitive edge and drive greater product adoption. The company’s strategic focus on expanding the hypertrophic cardiomyopathy category, along with its robust sales force, positions it well for future growth. The upcoming results from the phase 3 ACACIA trial in non-obstructive HCM (nHCM) are also crucial, as they could further define aficamten’s growth potential.
According to TipRanks, Romero is a 5-star analyst with an average return of 21.1% and a 53.33% success rate. Romero covers the Healthcare sector, focusing on stocks such as Cytokinetics, ACADIA Pharmaceuticals, and Xenon.
In another report released on November 10, RBC Capital also maintained a Buy rating on the stock with a $87.00 price target.